EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Trastuzumab deruxtecan in previously treated HER2 ‐positive metastatic or unresectable breast cancer: Real‐life data from the temporary use authorization program in France

Thierry Petit iD, Nawale Hajjaji, Eric-Charles Antoine, Marc-Antoine Benderra iD, Michel Gozy, Cyril Foa, Jean-Loup Mouysset, Julien Grenier, Mireille Mousseau, Audrey Mailliez, Mahasti Saghatchian, Emma Lachaier und 13 weitere

Cancer Medicine · 2024-05 · 13 (9)

DOI: 10.1002/cam4.7168 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Medicine, online erschienen am 11.05.2024. Verfasst von Thierry Petit und 24 weiteren Autor:innen. Beteiligte Einrichtung: Département d'Oncologie Médicale, Centre Paul Strauss, Strasbourg, France. Hauptthemen laut MEDLINE: Breast Neoplasms, Trastuzumab, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca France, Daiichi-Sankyo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Early access program (formerly cohort Temporary Authorization for Use) was granted for trastuzumab deruxtecan (T‐DXd) in France based on DESTINY‐Breast01 trial which demonstrated its efficacy and safety in HER2‐positive metastatic/unresectable breast cancer after ≥2 anti‐HER2‐based regimens received at metastatic stage. Method s This multicenter real‐world early access program included HER2‐positive metastatic/unresectable breast patients pretreated with at least two lines of anti‐HER2 regimens who received T‐DXd 5.4 mg/kg intravenously in monotherapy every 3 weeks.

Results

Four hundred and fifty‐nine patients (median age, 58 years; hormone receptor‐positive, 67%; brain metastases, 28.1%) received T‐DXd. Before inclusion, 81.7% of patients had radiation therapy and 76.5% had undergone surgery. Median number of prior metastatic treatment lines was four (range, 2–22); 99.8% patients had received trastuzumab, 94.8% trastuzumab emtansine and 79.3% pertuzumab. Follow‐up was performed from September 30, 2020 to March 30, 2021; when the early access program stopped, the median duration of T‐DXd treatment was 3.4 (range, 0–7.8) months. In 160 patients with available tumor assessment, objective response rate was 56.7% and 12.1% had progression. In 57 patients with available brain tumor assessment, complete or partial intracranial response was reported for 35.7% patients and 5.4% had progression. A total of 17 (3.7%) patients with interstitial lung disease (ILD) was reported with no cases of ILD‐related death.

Conclusions

In this early access program in patients with heavily pretreated HER2‐positive metastatic/unresectable breast cancer, T‐DXd had antitumor activity with a similar response to that reported in previous clinical studies. T‐DXd was well tolerated and no new safety signals were observed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsTrastuzumabErb-b2 Receptor Tyrosine KinasesHumansFemaleMiddle AgedFranceAgedAdultCamptothecinImmunoconjugatesAntineoplastic Agents, ImmunologicalAged, 80 and overTreatment Outcome

Stichwörter der Autor:innen

HER2‐positivebreast cancerearly‐access programmetastatic cancertrastuzumab deruxtecan

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine KinasesCamptothecinImmunoconjugatesAntineoplastic Agents, Immunologicaltrastuzumab deruxtecanERBB2 protein, human

Autor:innen und Institutionen

  • Département d'Oncologie Médicale, Centre Paul Strauss, Strasbourg, France.
  • Département de Cancérologie Sénologique, Centre Oscar Lambret, INSERM U1192, Laboratoire PRISM, Lille, France.
  • Département d'Oncologie Médicale, Clinique Hartmann, Neuilly-sur-Seine, France.
  • Département d'Oncologie Médicale, Hôpital Tenon, Paris, France.
  • Département de Radiothérapie-Oncologie, Clinique de l'Europe, Amiens, France.
  • Département d'Oncologie Médicale, Hôpital Saint-Joseph, Marseille, France.

ORCID-Profile: Thierry Petit, Marc-Antoine Benderra

Förderung

  • AstraZeneca France
  • Daiichi-Sankyo

Zitieren

APA

Petit, T., Hajjaji, N., Antoine, E. C., Benderra, M. A., Gozy, M., Foa, C., Mouysset, J. L., Grenier, J., Mousseau, M., Mailliez, A., Saghatchian, M., Lachaier, E., Desmoulins, I., Hennequin, A., Maes, P., Loirat, D., Ricci, F., Diéras, V., Berton, D., …, & Pierga, J. Y. (2024). Trastuzumab deruxtecan in previously treated HER2 ‐positive metastatic or unresectable breast cancer: Real‐life data from the temporary use authorization program in France. Cancer Medicine, 13(9). https://doi.org/10.1002/cam4.7168

Vancouver

Petit T, Hajjaji N, Antoine EC, Benderra MA, Gozy M, Foa C, et al. Trastuzumab deruxtecan in previously treated HER2 ‐positive metastatic or unresectable breast cancer: Real‐life data from the temporary use authorization program in France. Cancer Medicine. 2024;13(9). doi:10.1002/cam4.7168

BibTeX
@article{Petit2024,
  author = {Petit, Thierry and Hajjaji, Nawale and Antoine, Eric-Charles and Benderra, Marc-Antoine and Gozy, Michel and Foa, Cyril and Mouysset, Jean-Loup and Grenier, Julien and Mousseau, Mireille and Mailliez, Audrey and Saghatchian, Mahasti and Lachaier, Emma and Desmoulins, Isabelle and Hennequin, Audrey and Maes, Patricia and Loirat, Delphine and Ricci, Francesco and Diéras, Véronique and Berton, Dominique and Tiong, Florence Lai and Teixeira, Luis and Dohollou, Nadine and Lévy, Christelle and Bachelot, Thomas and Pierga, Jean-Yves},
  title = {Trastuzumab deruxtecan in previously treated HER2 ‐positive metastatic or unresectable breast cancer: Real‐life data from the temporary use authorization program in France},
  journal = {Cancer Medicine},
  year = {2024},
  volume = {13},
  number = {9},
  doi = {10.1002/cam4.7168}
}
Kostenlos starten →